Abstract

Hepatitis B virus (HBV) only infects humans and chimpanzees, posing major challenges for modeling HBV infection and chronic viral hepatitis. The major barrier in establishing HBV infection in non-human primates lies at incompatibilities between HBV and simian orthologues of the HBV receptor, sodium taurocholate co-transporting polypeptide (NTCP). Through mutagenesis analysis and screening among NTCP orthologues from Old World monkeys, New World monkeys and prosimians, we determined key residues responsible for viral binding and internalization, respectively and identified marmosets as a suitable candidate for HBV infection. Primary marmoset hepatocytes and induced pluripotent stem cell-derived hepatocyte-like cells support HBV and more efficient woolly monkey HBV (WMHBV) infection. Adapted chimeric HBV genome harboring residues 1–48 of WMHBV preS1 generated here led to a more efficient infection than wild-type HBV in primary and stem cell derived marmoset hepatocytes. Collectively, our data demonstrate that minimal targeted simianization of HBV can break the species barrier in small NHPs, paving the path for an HBV primate model.

Hepatitis B virus is an almost uniquely human-tropic pathogen for which model systems are scarce. Here, the authors determine key residues within the HBV receptor that form a barrier in the HBV life cycle in primates and identify marmosets as a model candidate for infection with simian-tropic HBV.

Details

Title
Targeted viral adaptation generates a simian-tropic hepatitis B virus that infects marmoset cells
Author
Liu, Yongzhen 1   VIAFID ORCID Logo  ; Cafiero, Thomas R. 1 ; Park, Debby 1 ; Biswas, Abhishek 2 ; Winer, Benjamin Y. 3 ; Cho, Cheul H. 4 ; Bram, Yaron 5 ; Chandar, Vasuretha 5 ; Connell, Aoife K. O’ 6 ; Gertje, Hans P. 6 ; Crossland, Nicholas 7   VIAFID ORCID Logo  ; Schwartz, Robert E. 5   VIAFID ORCID Logo  ; Ploss, Alexander 1   VIAFID ORCID Logo 

 Princeton University, Department of Molecular Biology, Princeton, USA (GRID:grid.16750.35) (ISNI:0000 0001 2097 5006) 
 Princeton University, Department of Molecular Biology, Princeton, USA (GRID:grid.16750.35) (ISNI:0000 0001 2097 5006); Princeton University, Research Computing, Office of Information Technology, Princeton, USA (GRID:grid.16750.35) (ISNI:0000 0001 2097 5006) 
 Princeton University, Department of Molecular Biology, Princeton, USA (GRID:grid.16750.35) (ISNI:0000 0001 2097 5006); Memorial Sloan-Kettering Cancer Center, New York, USA (GRID:grid.51462.34) (ISNI:0000 0001 2171 9952) 
 Visikol, Inc., Hampton, USA (GRID:grid.51462.34) 
 Weill Cornell Medicine, Division of Gastroenterology and Hepatology, Department of Medicine, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X) 
 Boston University, National Emerging Infectious Diseases Laboratories, Boston, USA (GRID:grid.189504.1) (ISNI:0000 0004 1936 7558) 
 Boston University, National Emerging Infectious Diseases Laboratories, Boston, USA (GRID:grid.189504.1) (ISNI:0000 0004 1936 7558); Boston University Chobanian & Avedisian School of Medicine, Department of Pathology and Laboratory Medicine, Boston, USA (GRID:grid.189504.1) (ISNI:0000 0004 1936 7558) 
Pages
3582
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2827005678
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.